deltatrials
Terminated PHASE2 INTERVENTIONAL 3-arm NCT04445064

Activity and Safety of Peptide-based Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck. (HN1901)

Activity and Safety of Peptide-based Immunotherapy in an Umbrella Window-of-opportunity Phase II Study in Patients With Squamous Cell Carcinoma of the Head and Neck.

Sponsor: Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Conditions Hypopharynx Squamous Cell Carcinoma Larynx Squamous Cell Carcinoma Oral Cavity Squamous Cell Carcinoma Oropharynx Squamous Cell Carcinoma
Interventions IO102 IO103
Updated 7 times since 2020 Last updated: Dec 8, 2025 Started: Aug 14, 2020 Primary completion: Jun 8, 2024 Completion: Mar 20, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

unmet primary endpoint

Other terminated trials from Cliniques universitaires Saint-Luc- Université Catholique de Louvain

See all terminations from Cliniques universitaires Saint-Luc- Université Catholique de Louvain

This PHASE2 trial investigates Hypopharynx Squamous Cell Carcinoma and Larynx Squamous Cell Carcinoma and is currently terminated or withdrawn. Cliniques universitaires Saint-Luc- Université Catholique de Louvain leads this study, which shows 7 recorded versions since 2020 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jul 2020 – ~Dec 2020 · 5 months · monthly snapshotRecruiting~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshotRecruiting~Jan 2021 – ~Jun 2022 · 17 months · monthly snapshotRecruiting~Jun 2022 – ~Jul 2024 · 25 months · monthly snapshotRecruiting~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotUnknown~Sep 2024 – ~Jan 2026 · 16 months · monthly snapshotUnknown~Jan 2026 – present · 6 months · monthly snapshotTerminated

Change History

7 versions recorded

  1. Jan 2026 — Present [monthly]

    Terminated PHASE2

    Status: Unknown → Terminated

  2. Sep 2024 — Jan 2026 [monthly]

    Unknown PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE2

    Status: Recruiting → Unknown

  4. Jun 2022 — Jul 2024 [monthly]

    Recruiting PHASE2

  5. Jan 2021 — Jun 2022 [monthly]

    Recruiting PHASE2

▶ Show 2 earlier versions

  1. Dec 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  2. Jul 2020 — Dec 2020 [monthly]

    Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Data source: Cliniques universitaires Saint-Luc- Université Catholique de Louvain

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations